A total of 162 Equity Offering deals (pending and completed) were announced in the Healthcare of the Asia-Pacific region, in the last twelve months resulting in a total deal value of over $28,043.9 million. In the LTM period, December 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $7,757.3 million, resulting in an average deal value of $352.6 million during that month. On the other hand, the month of December 2021 was the most prolific in terms of deal volume, recording a total of 22 deals, resulting in an average deal value of $352.6 million during that month.
Of the 162 deals, the deal secured between China Huadian Group Capital Holdings Co Ltd; China Yangtze Power Co Ltd; Guangzhou Development Zone Investment Group Co. Ltd and Dinghe Property Insurance Co., Ltd., was the largest Equity Offering deal in the Asia-Pacific Healthcare sector, which was valued at $1,013.0 million and was completed on December 14, 2021. The second-largest deal was between Aberdeen New India Investment Trust PLC; Abu Dhabi Investment Authority; Baillie Gifford Pacific Fund; Bharti AXA Life Insurance Company Ltd; Desjardins Emerging Markets Fund; Edelweiss Financial Services Ltd; Government of Singapore; HDFC Life Insurance Co Ltd; IIFL Special Opportunities Fund; Lazard Emerging Markets Fund; Max Life insurance Co Ltd; Monetary Authority of Singapore; Moraine Master; Morgan Stanley; NVIT Emerging Markets Fund; Partners Bay Master Fund; SBI Life Insurance Co Ltd; Segantii India Mauritius; SEI Institutional Investments Trust; Societe Generale SA; The New Economy Fund; Valiant Mauritius Partners FDI Limited; WCM Focused Emerging Markets Fund; Wf Asian Smaller Companies Fund Ltd and Star Health and Allied Insurance Company Ltd, while the third-largest deal was between Midea Group Co Ltd and China Resources Wandong Medical Equipment Co Ltd. The Aberdeen New India Investment Trust PLC; Abu Dhabi Investment Authority; Baillie Gifford Pacific Fund; Bharti AXA Life Insurance Company Ltd; Desjardins Emerging Markets Fund; Edelweiss Financial Services Ltd; Government of Singapore; HDFC Life Insurance Co Ltd; IIFL Special Opportunities Fund; Lazard Emerging Markets Fund; Max Life insurance Co Ltd; Monetary Authority of Singapore; Moraine Master; Morgan Stanley; NVIT Emerging Markets Fund; Partners Bay Master Fund; SBI Life Insurance Co Ltd; Segantii India Mauritius; SEI Institutional Investments Trust; Societe Generale SA; The New Economy Fund; Valiant Mauritius Partners FDI Limited; WCM Focused Emerging Markets Fund; Wf Asian Smaller Companies Fund Ltd-Star Health and Allied Insurance Company Ltd deal and the Midea Group Co Ltd-China Resources Wandong Medical Equipment Co Ltd deal were valued at $428.5 million and $323.9 million, respectively. The fourth-largest deal was between TPG Capital LP-Novotech Health Holdings valued at $255.0 million, whereas the deal between Sino Biopharmaceutical Ltd; Yifan Pharmaceutical Co Ltd-Yiyi Biopharmaceutical (Beijing) Co., Ltd. valued at $70.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $2,090.5 million and accounted for nearly 7.45% of the total deals (by value) announced during the last twelve months. The Asia-Pacific region accounted for 30.38% of the total Equity Offering deals done globally, and accounted for 0.24% of the total deal size on a global scale.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
United States of America
United States of America
Japan
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer